|
| 阿仑膦酸钠治疗男性骨质疏松症临床研究 |
| Clinical study of alendronate sodium in the treatment of male osteoporosis |
| |
| DOI：10.3969/j.issn.1006.7108.2013.07.017 |
| 中文关键词: 骨质疏松 阿仑膦酸钠 骨密度 骨标志物 |
| 英文关键词:Osteoporosis Alendronate sodium Bone mineral density Bone markers |
| 基金项目: |
|
| 摘要点击次数: 897 |
| 全文下载次数: 817 |
| 中文摘要: |
| 目的 探讨阿仑膦酸钠对男性骨质疏松症患者骨密度、血生化及骨标志物的影响。方法选择2012年1月~2013年1月在我科门诊及住院50岁以上男性骨质疏松患者共169例，每人每天服用元素钙600 mg，活性维生素D 0.25μg作为基础补充剂，每周服用阿仑膦酸钠70 mg，共治疗12个月。观察骨密度、骨标志物等指标，骨密度测定采用双能X线吸收法，骨标志物测定采用酶联免疫吸附法。结果 研究结果显示，治疗1年后，L2、L3、L2 -4、Neck、Ward's三角骨密度分别为0.791±0.150 g/cm2 ,0. 817±0. 149 g/cm2 ,0. 827±0.1S4 g/cm2,0.875±0. 153 g/cm2 ,0. 703±0. 138g/cm2,0.522±0. 133 g/cm2，均较治疗前0. 772±0. 144g/cm2 ,0. 800 ± 0. 156 g/cm2 ,0. 861±0. 168 g/cm2 ,0. 685±0.109 g/cm2,0.490±0. 121 g/cm2有明显提高，差异具有统计学意义(P<0.05)，其他部位骨密度无明显差异(P>0.05);治疗后血清CTX,BGP,BAP为0. 20±0. 11 ng/m1,7.73±4.11ng/ml,14. s7±7. 20 ng/ml，较治疗前0. 32±0.23 ng/ml,11.39±s.6 ng/ml,16. 17±8. 81 ng/ml显著降低，差异具有统计学意义(P<0.05)。结论 阿仑膦酸钠能有效降低破骨细胞活性，抑制骨破坏，显著提高骨量，对老年男性骨质疏松疗效显著。 |
| 英文摘要: |
| Objective To investigate the effect of alendronate sodium on blood biochemistry, bone markers, and bone mineral density in male patients with osteoporosis. Methods A total of 169 male patients above 50 years old with osteoporosis，who came to our hospital(out-patient department and in-patient department ) from January 2012 to January 2013，were selected. All the patients took calcium 600mg and active vitamin D 0.25μg per day as the basic supplements.Then they took sodium alendronate phosphonic acid 70mg every week，lasting for 12 months. Bone mineral density(BMD) and bone markers were observed. BMD was measured using dual-energy X-ray absorptiometry, and bone markers were measured using enzyme linked immunosorbent assay. Results As the results indicated, after 1-year treatment, BMD of L2，L3，L2-4，the femoral neck，and Ward’s triangle was 0. 791±0. 150 g/cm2，0. 817±0. 149 g/cm2，0. 827±0. 154 g/cm2，0. 875±0. 153 g/cm2，0. 703±0. 138 g/cm2，and 0. 522±0. 133 g/cm2，respectively，which was higher than that before the treatment ( 0. 772±0. 144 g/cm2，0. 800±0. 156 g/cm2，0. 861±0.168 g/cm2，0.685±0. 109 g/cm2，and 0. 490±0. 121 g/cm2，respectively ).And the difference was statistically significant(P<0. 05).However, BMD of other parts showed no significant difference(P>0. 05).Serum levels of CTX，BGP, and BAP after the treatment were 0. 20± 0. 11 ng/ml, 7. 73± 4. 11 ng/ml, and 14. 57±7. 20 ng/ml，respectively, which were lower than those before the treatment ( 0. 32±0. 23 ng/ml, 11. 39±5.6 ng/ml, and 16. 17±8. 81 ng/ml，respectively ).And the difference was statistically significant ( P<0.05).Conclusion Alendronate can decrease osteoclast activity, inhibit bone destruction，and improve bone mass significantly. It has significant therapeutic effect on osteoporosis in elderly men. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|